Effects of AGTR1 A1166C gene polymorphism in patients with heart failure treated with candesartan

Annals of Pharmacotherapy

Volumn 42, Issue 7-8, 2008, Pages 925-932

  De Denus, Simon ^a   Zakrzewski Jakubiak, Marcin ^b   Dubé, Marie Pierre ^c   Bélanger, François ^d   Lepage, Serge ^e   Leblanc, Marie Hélène ^f   Gossard, Denis ^g   Ducharme, Anique ^a,b   Racine, Normand ^a,b   Whittom, Lucette ^a   Lavoie, Joel ^a   Touyz, Rhian M ^h,i   Turgeon, Jacques ^b,d   White, Michel ^a,b  

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF MONTREAL   (Canada)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^f LAVAL UNIVERSITY   (Canada)

^g Hopital du Haut Richelieu   (Canada)

^h OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

ⁱ UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Angiotensin; Candesartan; Heart failure; Pharmacogenetics

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN 1 RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CANDESARTAN; DIGITALIS GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; NEUROHORMONE; PLACEBO; SPIRONOLACTONE;

A1166C GENE; ADULT; ALLELE; ANALYSIS OF VARIANCE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; FEMALE; GENE; GENE FREQUENCY; GENOTYPE; HEART FAILURE; HEMODYNAMICS; HETEROZYGOTE; HUMAN; LONG TERM CARE; MALE; MULTICENTER STUDY; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

AGED; ANALYSIS OF VARIANCE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BLOOD PRESSURE; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; POLYMORPHISM, GENETIC; RECEPTOR, ANGIOTENSIN, TYPE 1; TETRAZOLES;

EID: 48249089617     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K657     Document Type: Article

References (47)

1. Martineau P, Goulet J. New competition in the realm of renin-angiotensin axis inhibition; the angiotensin II receptor antagonists in congestive heart failure. Ann Pharmacother 2001;35:71-84. DOI 10.1345/aph.19307
2. Farquharson CA, Struthers AD. Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure. J Am Coll Cardiol 2002;39:767-75.
3. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-71.
4. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
5. Lee DS, Pencina MJ, Benjamin EJ, et al. Association of parental heart failure with risk of heart failure in offspring. N Engl J Med 2006;355:138-47.
6. Rice GI, Jones AL, Grant PJ, Carter AM, Turner AJ, Hooper NM. Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin- converting enzyme 2, and neprilysin in a family study. Hypertension 2006;48:914-20.
7. McNamara DM, Holubkov R, Postava L, et al. Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol 2004;44:2019-26.
8. Ozdemir V, Williams-Jones B, Cooper DM, Someya T, Godard B. Mapping translational research in personalized therapeutics: from molecular markers to health policy. Pharmacogenomics 2007;8:177-85.
9. White M, Lepage S, Lavoie J, et al. Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure. J Card Fail 2007;13:86-94.
10. 2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J Hypertens 2003;21:621-4.
11. Kurland L, Melhus H, Karlsson J, et al. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J Hypertens 2002;20:657-63.
12. Kurland L, Melhus H, Karlsson J, et al. Aldosterone synthase (CYP11B2)-344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. Am J Hypertens 2002;15:389-93.
13. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-6.
14. Grant FD, Romero JR, Jeunemaitre X, et al. Low-renin hypertension, altered sodium homeostasis, and an alpha-adducin polymorphism. Hypertension 2002;39:191-6.
15. McNamara DM, Holubkov R, Postava L, et al. Effect of the Asp298 variant of endothelial nitric oxide synthase on survival for patients with congestive heart failure. Circulation 2003;107:1598-602.
16. Forleo C, Resta N, Sorrentino S, et al. Association of beta-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy. Am J Med 2004;117:451-8.
17. Fernandez-Llama P, Poch E, Oriola J, Botey A, Rivera F, Revert L. Angiotensinogen gene M235T and T174M polymorphisms in essential hypertension: relation with target organ damage. Am J Hypertens 1998;11:439-44.
18. Kupari M, Hautanen A, Lankinen L, et al. Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function. Circulation 1998;97:569-75.
19. 2 receptor gene. Biochem Biophys Res Commun 1995;211:234-40.
20. Morrison AC, Doris PA, Folsom AR, Nieto FJ, Boerwinkle E. G-protein beta3 subunit and alpha-adducin polymorphisms and risk of subclinical and clinical stroke. Stroke 2001;32:822-9.
21. Hibi K, Ishigami T, Tamura K, et al. Endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction. Hypertension 1998;32:521-6.
22. Fatini C, Soft F, Sticchi E, et al. Influence of endothelial nitric oxide synthase gene polymorphisms (G894T, 4a4b, T-786C) and hyperhomocysteinemia on the predisposition to acute coronary syndromes. Am Heart J 2004;147:516-21.
23. Kaye DM, Smirk B, Williams C, Jennings G, Esler M, Holst D. Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics 2003;13:379-82.
24. Shanmugam V, Sell KW, Saha BK. Mistyping ACE heterozygotes. PCR Methods Appl 1993;3:120-1.
25. Araujo MA, Goulart LR, Cordeiro ER, et al. Genotypic interactions of renin-angiotensin system genes in myocardial infarction. Int J Cardiol 2005;103:27-32.
26. Hingorani AD, Brown MJ. A simple molecular assay for the C1166 variant of the angiotensin II type 1 receptor gene. Biochem Biophys Res Commun 1995;213:725-9.
27. Schmidt S, Beige J, Walla-Friedel M, Michel MC, Sharma AM, Ritz E. A polymorphism in the gene for the angiotensin II type 1 receptor is not associated with hypertension. J Hypertens 1997;15:1385-8.
28. Anand IS, Florea VG, Fisher L. Surrogate end points in heart failure. J Am Coll Cardiol 2002;39:1414-21.
29. Baudin B. Polymorphism in angiotensin II receptor genes and hypertension. Exp Physiol 2005;90:277-82.
30. Spiering W, Kroon AA, Fuss-Lejeune MM, Daemen MJ, de Leeuw PW. Angiotensin II sensitivity is associated with the angiotensin II type 1 receptor A(1166)C polymorphism in essential hypertensives on a high sodium diet. Hypertension 2000;36:411-6.
31. van Geel PP, Pinto YM, Voors AA, et al. Angiotensin II type 1 receptor A1166C gene polymorphism is associated with an increased response to angiotensin II in human arteries. Hypertension 2000;35:717-21.
32. Tiret L, Bonnardeaux A, Poirier O, et al. Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction. Lancet 1994;344:910-3.
33. Kainulainen K, Perola M, Terwilliger J, et al. Evidence for involvement of the type 1 angiotensin II receptor locus in essential hypertension. Hypertension 1999;33:844-9.
34. Belz GG. Angiotensin II dose-effect curves and Schild regression plots for characterization of different angiotensin II AT1 receptor antagonists in clinical pharmacology. Br J Clin Pharmacol 2003;56:3-10.
35. Spiering W, Kroon AA, Fuss-Lejeune MJ, de Leeuw PW. Genetic contribution to the acute effects of angiotensin II type 1 receptor blockade. J Hypertens 2005;23:753-8.
36. de Denus S, Pharand C, Williamson DR. Brain natriuretic peptide in the management of heart failure: the versatile neurohormone. Chest 2004;125:652-68.
37. Anand IS, Latini R, Florea VG, et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 2005;112:1428-34.
38. Miller JA, Thai K, Scholey JW. Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II. Kidney Int 1999;56:2173-80.
39. Redon J, Luque-Otero M, Martell N, Chaves FJ. Renin-angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients. Pharmacogenomics J 2005;5:14-20.
40. Kurland L, Melhus H, Karlsson J, et al. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens 2001;19:1783-7.
41. Bleske BE. Evolution and pathophysiology of chronic systolic heart failure. Pharmacotherapy 2000;20(suppl):349S-58S.
42. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724-9.
43. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006;354: 1685-97.
44. McClellan KJ, Goa KL. Candesartan cilexetil. A review of its use in essential hypertension. Drugs 1998;56:847-69.
45. Serneri GG, Boddi M, Cecioni I, et al. Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function. Circ Res 2001;88:961-8.
46. Swedberg K, Eneroth P, Kjekshus J, Snapinn S. Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). Am J Cardiol 1990;66:40D-4D.
47. Cohen Solal A, Jondeau G, Beauvais F, Berdeaux A. Beneficial effects of carvedilol on angiotensin-converting enzyme activity and renin plasma levels in patients with chronic heart failure. Eur J Heart Fail 2004;6:463-6.